Straumann stock steadies after Q2 2026 beat and CEO transition update
Published on 08/20/2026 at 17:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Straumann Holding AG (ISIN CH0012280076) stock is trading close to its recent Swiss closing price after the company reported a Q2 2026 earnings beat and confirmed a CEO transition scheduled for December, giving investors fresh data and leadership context as of August 20, 2026. The latest trading indications show the shares quoted at EUR104.00 on Tradegate and CHF97.22 for the most recent Swiss Exchange close, framing the current valuation discussion around Straumann.
Q2 2026 beat and CEO change set the tone
Recent commentary on Straumann highlights that the group delivered Q2 2026 results ahead of expectations, described as a beat versus analyst forecasts, while also confirming that its current CEO will be replaced in December 2026. One earnings overview notes that Straumann Holding stock closed at CHF97.22 on the day its latest figures were released, positioning the shares below an internal discounted cash flow estimate of CHF160.06 that was used to illustrate valuation upside potential at that time. The same analysis points out that this latest close also sits below an average target price of CHF110.94 cited in a market-data snapshot, suggesting that the market is currently valuing Straumann below the level implied by consensus price targets.
A separate German-language market report states that Straumann shares were quoted at EUR104.00 on August 20, 2026 at 8:00 a.m. local trading time on the Lang & Schwarz platform, with the move compared against a prior reference of EUR102.15 to illustrate recent trading levels. That comparison shows the current quote slightly above the earlier EUR102.15 mark, indicating that Straumann has added value in euro terms over this short period even though the day-over-day percentage change at the snapshot time was reported as essentially flat.
Latest trading levels and performance signals
Market-data pages compiled on August 20, 2026 show Straumann Ag trading at CHF97.22 per share as its latest Swiss closing price as of August 19, 2026. This level is used consistently across multiple snapshots as the most recent close on the Swiss Exchange, and it anchors near-term performance metrics such as the one-day change and year-to-date move cited in summary tables. One trading overview reports a recent five-day performance of minus 2.45 percent and a change since the start of the year of minus 5.38 percent, indicating that Straumann shares have given up ground both over the last week and since January 1, 2026 despite the Q2 earnings beat. In contrast, another snapshot lists a positive year-to-date change of plus 3.79 percent in the euro quotation at EUR104.00, underscoring that performance readings can differ between venues and reference dates but still point to moderate volatility rather than a sharply trending stock.
For investors monitoring valuation, the relationship between the CHF97.22 closing price and the CHF160.06 discounted cash flow estimate is notable. The closing level on the day of the results represents a discount of more than 40 percent to that internal fair value estimate, which is used in one analysis to argue that Straumann trades at a rich valuation on conventional multiples yet still below fundamental value on a cash flow basis. When set against the CHF110.94 average target price indicated in the same data set, the CHF97.22 close shows Straumann trading roughly CHF13.72 below that consensus level, illustrating a gap between the market price and analyst expectations that may partially reflect caution around execution, margins, or the upcoming CEO transition.
Financial results hub and historical growth context
Straumann’s own financial results hub provides a comprehensive history of its performance from 2021 through 2025, offering useful context for interpreting the current Q2 2026 beat. The results table shows that net revenue rose from CHF2,021.9 million in 2021 to CHF2,605.4 million in 2025, an increase of CHF583.5 million over four years. The associated year-on-year growth rates were listed as 41.8 percent for 2021, 14.8 percent for 2022, 3.7 percent for 2023, 10.0 percent for 2024, and 4.1 percent for 2025, demonstrating that Straumann moved from very high growth in 2021 to more moderate expansion in subsequent years while still increasing its top line each year.
The same financial summary records gross profit climbing from CHF1,540.0 million in 2021 to CHF1,786.9 million in 2025. During that period, the gross margin declined from 76.2 percent in 2021 to 68.6 percent in 2025, indicating that Straumann maintained growth in absolute gross profit but saw some pressure on margins as the business scaled and cost structures evolved. Operating profit before depreciation and amortization (EBITDA) is shown as CHF652.4 million in 2021 compared with CHF738.2 million in 2025, corresponding to EBITDA margins of 32.3 percent and 28.3 percent respectively. That pattern again highlights Straumann’s ability to expand earnings in franc terms over several years while managing margin compression.
Operating profit (EBIT) figures in the same table illustrate a similar story. EBIT is reported as CHF542.6 million for 2021, CHF535.3 million for 2022, CHF598.1 million for 2023, CHF601.0 million for 2024, and CHF549.2 million for 2025. The associated growth line shows that EBIT growth has fluctuated, including strong increases in some years and negative growth in others, with one entry recording an 8.6 percent decline for 2025 relative to the prior year. Net profit figures demonstrate that Straumann remained profitable throughout the period, posting CHF399.3 million in 2021, CHF434.8 million in 2022, CHF448.9 million in 2023, CHF459.5 million in 2024, and CHF358.0 million in 2025. Basic earnings per share moved from CHF2.49 in 2021 to CHF2.24 in 2025, showing that while Straumann sustained solid earnings, EPS trends have not been uniformly upward over the five-year span.
These historical figures are labeled clearly as covering fiscal years 2021 through 2025 and therefore serve primarily as a background comparison for the latest Q2 2026 performance, which is reported separately in current commentary as a beat versus expectations. Since the fiscal 2025 period ended within the last 24 months relative to August 20, 2026, the 2025 numbers can still be used as a benchmark for revenue scale, profitability, and cash generation. For example, the free cash flow line indicates that Straumann generated CHF290.2 million of free cash flow in 2025 compared with CHF440.6 million in 2021, and dividend data shows proposed dividends rising from CHF107.41 million in 2021 to CHF159.5 million in 2025, with dividend per share climbing from CHF0.80 to CHF1.00 over the same time frame. Those trends support the view that Straumann has combined growth with shareholder distributions while navigating margin dynamics.
Margins, guidance and analyst perspective
The Q2 2026 beat has been linked in commentary to Straumann reaffirming its margin target, which is important in the context of the historic margin compression seen between 2021 and 2025. Historical gross margin data in the company’s results hub show a decline from 76.2 percent in 2021 to 68.6 percent in 2025, but the reaffirmed margin goal indicates management’s commitment to stabilizing or improving profitability even as Straumann continues to invest in growth initiatives and product development. Similarly, EBITDA margins moving from 32.3 percent in 2021 to 28.3 percent in 2025 underscore the balancing act between operating leverage and costs, and any Q2 2026 commentary that highlights margin improvement would therefore be interpreted against this backdrop.
Analyst views reflected in recent market-data snapshots and valuation write-ups present Straumann as a company that commands a premium valuation while still offering upside against discounted cash flow and consensus target estimates. The closing price of CHF97.22 is compared with the CHF160.06 discounted cash flow estimate to illustrate potential undervaluation, and the CHF110.94 average target price suggests that consensus expects Straumann to trade higher than its current value if it continues to deliver on its growth and margin objectives. At the same time, short-term performance data indicate that Straumann shares have experienced negative percentage changes over recent periods in some venues, which can be associated with profit-taking after prior gains, sector rotation within healthcare, or investor caution ahead of the CEO handover.
The CEO transition itself, scheduled for December 2026, is a key qualitative factor alongside the quantitative metrics. The confirmation that Straumann will have a new chief executive at the end of 2026 introduces a leadership variable that investors must weigh against the company’s long history of revenue growth, profitability, and dividend expansion. On the one hand, incoming leadership can bring fresh strategic perspectives, potentially reinforcing Straumann’s focus on innovation in dental implants, clear aligners, and digital dentistry solutions. On the other hand, leadership change always carries execution risk, particularly when margin stabilization and valuation normalization are central themes in the investment case.
Straumann’s business and flagship solutions
Straumann is globally recognized for its portfolio of dental implant systems, prosthetics, and associated digital solutions that support restorative and orthodontic treatments. The company’s business model is built around providing high-quality, clinically proven products that enable dentists and specialists to deliver predictable outcomes for patients requiring tooth replacement or correction. Straumann’s implant systems typically feature a combination of fixtures, abutments, and prosthetic components designed to integrate with bone and soft tissue, with an emphasis on long-term durability and aesthetic results.
In addition to implants, Straumann has invested in clear aligner technology and digital orthodontics, reflecting the broader market shift toward minimally invasive, aesthetically focused treatments. Clear aligner solutions allow practitioners to treat malocclusions with transparent, removable appliances guided by digital treatment planning software. These systems rely on accurate three-dimensional scans and simulation tools to design staged tooth movements, and Straumann’s offerings are integrated into broader digital workflows that include intraoral scanners, planning platforms, and fabrication technologies.
The company also supports its product portfolio with education and training for clinicians, ensuring that practitioners can adopt Straumann solutions effectively and safely. By combining products, digital tools, and professional development, Straumann aims to strengthen its competitive position in the high-growth segments of the dental market. This integrated approach is relevant for investors because it underpins Straumann’s ability to maintain pricing power and defend margins even as competition intensifies.
Share price context and investor view
As of August 19, 2026, Straumann’s latest closing price on the Swiss Exchange stood at CHF97.22, and market-data summaries on August 20, 2026 continue to reference this level as the most recent benchmark. Euro-quoted shares were indicated at EUR104.00 on Tradegate at 10:56 a.m. local time on August 20, 2026, with associated tables showing a five-day change of minus 0.05 percent and a change since the start of the year of minus 5.75 percent, alongside a positive metric of plus 3.79 percent in one summarized view. Taken together, these figures suggest that Straumann stock has been relatively steady in the very short term while experiencing modest negative performance over longer intervals in some venues.
For investors, the key takeaway is that Straumann stock now reflects a combination of solid historical growth, a Q2 2026 earnings beat, a confirmed CEO transition in December 2026, and valuation metrics that show the shares trading below both discounted cash flow estimates and the average target price cited in recent data. The historical revenue and earnings trends from 2021 to 2025 show that Straumann grew net revenue from CHF2,021.9 million to CHF2,605.4 million and maintained profitability with net profit of CHF358.0 million in 2025, while gradually increasing dividends to a proposed CHF159.5 million with CHF1.00 per share for 2025. In the context of the current CHF97.22 share price and the CHF110.94 average target, those fundamentals underpin a view of Straumann as a company with an established record that is now entering a new leadership phase, with margins and valuation likely to remain at the center of investor discussions.
Read more
Straumann financial results hub
Dental implant systems as a core product
Straumann’s dental implant systems sit at the core of its business and exemplify the company’s approach to combining clinical science with product engineering. These systems typically use titanium or titanium-alloy fixtures designed for osseointegration, the process by which bone tissue bonds to the implant surface. Over the years, Straumann has introduced surface treatments and design refinements intended to accelerate healing and increase the success rate of implant procedures, which has helped the company build a reputation among oral surgeons and implantologists.
Implant treatment workflows often begin with diagnostic imaging and planning, where Straumann’s digital tools can support clinicians in determining implant position, angulation, and prosthetic design. Once the fixture is placed, a healing period follows, after which the abutment and prosthetic crown or bridge are attached. Straumann offers a range of abutment designs and restorative options, including screw-retained and cement-retained solutions, to accommodate different clinical scenarios and aesthetic requirements. The company’s emphasis on compatibility across components allows practitioners to tailor treatments while maintaining system integrity.
From an investor standpoint, the implant business is important because it contributes meaningfully to Straumann’s revenue base and is supported by durable demand drivers such as aging populations, higher expectations for oral health, and rising disposable incomes in many markets. The historical revenue growth from CHF2,021.9 million in 2021 to CHF2,605.4 million in 2025, combined with steady gross profit expansion, indicates that Straumann has been able to capitalize on these trends while continuing to invest in product innovation and market development.
Straumann stock and current valuation snapshot
In the latest valuation snapshot as of August 20, 2026, Straumann stock is framed by its recent Swiss closing price of CHF97.22 and the EUR104.00 quotation on Tradegate, along with performance metrics that highlight modest negative changes over certain intervals. These market figures, taken together with the CHF160.06 discounted cash flow estimate and the CHF110.94 average target price cited in commentary, offer a structured view of where Straumann currently trades relative to modeled fair value and consensus expectations. For investors evaluating the shares, the combination of a Q2 2026 earnings beat, reaffirmed margin targets, and an upcoming CEO transition in December 2026 suggests that Straumann is in a phase where execution on profitability and strategic continuity will be closely watched, even as its long-term growth story in dental implants, clear aligners, and digital dentistry remains intact.
Fact box
Company: Straumann Holding AG
ISIN: CH0012280076
Ticker: STMN
Exchange: SIX Swiss Exchange
Price (as of August 19, 2026, 4:30 p.m. local exchange time): CHF97.22
Sector / Industry: Healthcare - Medical equipment and supplies
Index membership: Swiss market index constituent
